VRTX — Vertex Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapNeutral

Annual income statement for Vertex Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	6,206	7,574	8,931	9,869	11,020
Cost of Revenue
Gross Profit	5,469	6,670	7,850	8,607	9,490
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	3,349	4,792	4,623	6,037	11,253
Operating Profit	2,856	2,782	4,307	3,832	-233
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	3,117	2,730	4,232	4,380	249
Provision for Income Taxes
Net Income After Taxes	2,712	2,342	3,322	3,620	-536
Minority Interest
Net Income Before Extraordinary Items
Net Income	2,712	2,342	3,322	3,620	-536
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	2,712	2,342	3,322	3,620	-536
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	10.3	9.01	13.3	15.9	15.9